viernes, 5 de agosto de 2016

Clinical Trials Search Results - National Cancer Institute

Clinical Trials Search Results - National Cancer Institute

National Cancer Institute banner



National Cancer Institute





Laparoscopic Approach to Cervical Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LACC001, NCI-2014-01556, NCT00614211
Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin or Carboplatin and Etoposide
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CALGB 30610/RTOG 0538, NCI-2009-00470, CDR0000588879, RTOG 0538, CALGB-30610, NCT00632853
Sorafenib Long Term Extension Program (STEP)
Status: Active
Phase: Phase III
Type: Treatment
Age: 16 and over
Trial IDs: 12311, NCI-2012-01207, 2007-002604-17, NCT00625378
Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 21 and under at the time of definitive surgery
Trial IDs: ACNS0333, NCI-2009-00337, CDR0000592812, COG-ACNS0333, NCT00653068
Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients with Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Prevention
Age: 18 and over
Trial IDs: GOG-0225, NCI-2009-00595, CDR0000594600, NCT00719303
Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: LF-0208, NCI-2009-01425, NCT00706862
Efficacy of Adjuvant Mitotane Treatment (ADIUVO)
Status: Active
Phase: Phase III
Type: Treatment
Age: Over 18
Trial IDs: EudraCT 2007-007262-38, NCI-2014-00699, NCT00777244
Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Educational/Counseling/Training
Age: 18 and over
Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208
A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Comparison to Imatinib in Patients With Gastro-Intestinal Stromal Tumour in First Line Medical Treatment
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: AB04030, NCI-2011-02630, NCT00812240
Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy
Status: Active
Phase: Phase III
Type: Supportive care
Age: 18 and over
Trial IDs: 20070782, NCI-2010-00172, NCT00858364
Radiation Therapy or Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Anaplastic Glioma or Low Grade Glioma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: N0577, NCI-2011-01915, CDR0000640442, EORTC-26081-22086, EudraCT-2008-007295-14, NCCTG-N0577, NCT00887146
F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets
Status: Active
Phase: Phase III
Type: Diagnostic
Age: 18 and over
Trial IDs: AMI-2008-01, NCI-2014-02587, NCT00882609
Azacitidine in Preventing Relapse in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndrome Previously Treated with Donor Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 to 75
Trial IDs: 2008-0503, NCI-2012-01259, NCI-2009-01513, NCT00887068
TK008: Efficacy Study on the Strategy of HSV-Tk Engineering Donor Lymphocytes to Treat Patients With High Risk Acute Leukemia
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TK008, NCI-2011-03649, 2009-012973-37, NCT00914628
Radiation Therapy with or without Cetuximab in Treating Patients Who Have Undergone Surgery for Locally Advanced Head and Neck Cancer
Status: Active
Phase: Phase III
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG-0920, NCI-2011-00878, CDR0000651536, NCT01311063, NCT00956007
Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: RTOG 0724/GOG-0724, NCI-2011-01973, CDR0000654709, GOG-0724, RTOG-0724, NCT00980954
Risk-Based Therapy in Treating Younger Patients with Newly Diagnosed Liver Cancer
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 21 and under
Trial IDs: AHEP0731, NCI-2011-01975, CDR0000654889, COG-AHEP0731, NCT02265692, NCT00980460
Neurotropic Melanoma of the Head and Neck
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: TROG 08.09, NCI-2015-00466, 2009/039, ACTRN12610000478011, NCT00975520
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Status: Temporarily closed
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 60 and over
Trial IDs: E2906, NCI-2011-01992, CDR0000659585, ECOG-E2906, NCT01041703
Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 0 to 21
Trial IDs: SJBC3, NCI-2011-01251, NCI-2010-00129, NCT01046825
Everolimus in Treating Patients with Kidney Cancer Who Have Undergone Surgery
Status: Active
Phase: Phase III
Type: Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: S0931, NCI-2011-02028, CDR0000668388, SWOG-S0931, NCT01120249
Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ACNS0831, NCI-2011-02029, CDR0000668560, COG-ACNS0831, NCT01096368

No hay comentarios:

Publicar un comentario